Submission of readable Copy of Audited Finacial Results along with Audit Report of the Company for the Quarter and Year Financial ended 31st March, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.4 pts more than Nifty Microcap 250 and 1.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Adline Chem Lab Ltd has resubmitted a clearer copy of its audited financial results for the quarter and year ended March 31, 2025, after the original filing on May 9, 2025 was hard to read. For FY25, the company reported almost zero revenue from operations (Rs 0.01 lakh) and a net loss of Rs 13.22 lakhs, narrower than the Rs 27.18 lakh loss in FY24 (restated). The Q4 FY25 result showed a profit of Rs 20.94 lakhs, but this came entirely from a one-time other income of Rs 24.89 lakhs labelled 'Changes due to Modification of Financial Liabilities' — not from any business activity. The auditor's report carries no qualifications. On the balance sheet, other equity is deeply negative at Rs (733.95) lakhs, making net worth negative, while total borrowings stand at roughly Rs 284.62 lakhs. Operating cash flow was negative at Rs (22.61) lakhs and the company relied on fresh borrowings of about Rs 37.83 lakhs to stay afloat.
The company is effectively non-operational on the revenue side, sitting with negative net worth and accumulated losses that exceed its share capital, funded largely by debt. The Q4 profit is not from operations but from a one-time accounting adjustment, so shareholders should not read it as a business turnaround. Stock price and shareholder value remain at risk until real revenue and sustainable profits return.